managlinat dialanetil
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00290940)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Fructose-1,6-bisphosphataseINHIBITOR
FBP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cs 917
- cs-917
- cs-917
- cs-917
- cs917 cpd
- gp3034
- gp 3034
- gp-3034
- managlinat dialanetil
- mb06322
- mb 06322
- mb-06322
- mb-6322
- n,n'-((5-(2-amino-5-(2-methylpropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(alanine) diethyl ester
- r132917
- r 132917
- r-132917
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00290940 | Phase 2 | Jan 1, 2006 | Daiichi Sankyo |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 1 | 1 | 1 | 2006 |
1 organizations
Page 1 / 1